Project Grant R21AI193384
Award Date
7/9/25
Completion Date
6/30/27
Dollars Obligated
$430K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research to develop an immunocompetent ferret model to study the spinal pathology associated with Enterovirus D68 (EV-D68) infection and acute flaccid myelitis (AFM). The $217,976 award, effective from February 1, 2025 to January 31, 2027, will enable the grantee, The Henry M. Jackson Foundation for...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research on manipulating the DNA damage response and proteome on viral genomes during herpes simplex virus (HSV) infection. The $651,832 award, with a project period from November 2024 to October 2029, will enable researchers at The Children's Hospital of Philadelphia to conduct a multi-modal proteomic...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $729,006 to The Children's Hospital of Philadelphia Research Institute to conduct research on how adenovirus manipulates host RNA-binding proteins to exploit cellular RNA processing pathways and overcome host defenses. The 5-year project, running from January 2025 to December 2029, will employ innovative proteomics and...
This $477,226 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to discover novel antiviral systems in microbial eukaryotes. The research will focus on understanding how the amoeba genus Acanthamoeba defends against giant viruses called Megavirales, and then expand that knowledge to other microbial eukaryotes. The project will leverage cutting-edge AI techniques and...
This Project Grant award, valued at $792,687.00 and issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to define the structural features of sialoglycans necessary for influenza A virus (IAV) infection and adaptation across various host species. The key activities under this award include: 1) using CRISPR/Cas9 techniques to truncate different types of sialoglycans in human lung...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $242,310 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Trustees of Boston University's Medical Campus to establish a human intestinal organoid model for studying late-stage Ebola virus and Marburg virus infections. The project aims to characterize how these filovirus infections compromise the integrity of the intestinal epithelial barrier and disrupt ion flux, which can lead to...
This $583,047 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to understand how Rift Valley Fever Virus (RVFV) disseminates from the site of infection in the skin to the central nervous system (CNS). The project aims to establish the routes and mechanisms by which RVFV invades the CNS following peripheral exposure, using novel rodent CNS infection models...
This Project Grant award of $414,482 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to develop an improved oncolytic virus therapy for treating glioblastoma, an aggressive type of brain cancer. The key goals are to enhance the therapeutic efficacy of the Semliki Forest Virus (SFV) through directed evolution and engineering the virus to express a cancer-targeting peptide. The research aims to create a...
This Project Grant award of $536,871 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to identify pan-arenavirus sites of vulnerability through machine learning and artificial neural network molecular screening of small molecules against arenavirus glycoprotein complexes (GPC) and RNA polymerases (RNAP). The proposed research seeks to define molecular specificities and commonalities across...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a 2-year, $544,500 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to the Texas Biomedical Research Institute to characterize a novel mouse model for studying the neurological impacts of Chikungunya virus infection. The research aims to determine the mechanisms by which Chikungunya virus infects the brain and evaluate whether the mouse model develops the...